VolitionRX(VNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VNRX VolitionRX

Market Closed 07-24 16:00:00 EDT

1.00

-0.08

-7.41%

盘后1.04

+0.04+4.00%

19:34 EDT

High1.10	Low0.9900	Vol176.84K
Open1.10	D1 Closing1.08	Amplitude10.19%
Mkt Cap12.04M	Tradable Cap10.72M	Total Shares12.04M
T/O181.49K	T/O Rate1.65%	Tradable Shares10.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VNRX","market":"US","secType":"STK","nameCN":"VolitionRX","latestPrice":1,"timestamp":1784923200000,"preClose":1.08,"halted":0,"volume":176835,"hourTrading":{"tag":"盘后","latestPrice":1.04,"preClose":1,"latestTime":"19:34 EDT","volume":15850,"amount":16300.22,"timestamp":1784936050027,"change":0.04,"changeRate":0.04,"amplitude":0.04},"delay":0,"changeRate":-0.07407407407407414,"floatShares":10722594,"shares":12044300,"eps":-4.205769,"marketStatus":"Market Closed","change":-0.08,"latestTime":"07-24 16:00:00 EDT","open":1.1,"high":1.1,"low":0.99,"amount":181494.1247955,"amplitude":0.101852,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.205769,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1423198800000,"exchange":"AMEX","adjPreClose":1.08,"preHourTrading":{"tag":"盘前","latestPrice":1.1,"preClose":1.08,"latestTime":"08:23 EDT","volume":173,"amount":190.3,"timestamp":1784895781168,"change":0.02,"changeRate":0.018519,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.04,"preClose":1,"latestTime":"19:34 EDT","volume":15850,"amount":16300.22,"timestamp":1784936050027,"change":0.04,"changeRate":0.04,"amplitude":0.04},"volumeRatio":0.7014027657283819,"impliedVol":1.9914,"impliedVolPercentile":0.936},"requestUrl":"/m/hq/s/VNRX","defaultTab":"news","newsList":[{"id":"2653783869","title":"Volitionrx Held Annual Shareholder Meeting; 4,261,161 Shares Represented by Proxy or in Person","url":"https://stock-news.laohu8.com/highlight/detail?id=2653783869","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653783869?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:22","pubTimestamp":1784665359,"startTime":"0","endTime":"0","summary":"VolitionRx held annual shareholder meeting; 4,261,161 shares represented by proxy or in personVolitionRX held its annual shareholder meeting on July 17, 2026.Shareholders backed a charter amendment cu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL8M6hRb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653270771","title":"Volitionrx Posts Corporate Deck Outlining Nu.q Licensing Strategy Across Cancer, Sepsis and Veterinary Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2653270771","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653270771?lang=en_us&edition=fundamental","pubTime":"2026-07-21 21:04","pubTimestamp":1784639062,"startTime":"0","endTime":"0","summary":"VolitionRx posts corporate deck outlining Nu.Q licensing strategy across cancer, sepsis and veterinary testingVolitionRX outlined a partnership-led strategy to monetize its Nu.Q platform through licen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL4bsj09:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650997530","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolus (EOLS), Alkermes (ALKS) and VolitionRX (VNRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650997530","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650997530?lang=en_us&edition=fundamental","pubTime":"2026-07-08 23:50","pubTimestamp":1783525804,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Evolus (EOLS), Alkermes (ALKS) and VolitionRX (VNR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-evolus-eols-alkermes-alks-and-volitionrx-vnrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-evolus-eols-alkermes-alks-and-volitionrx-vnrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","MEDX","BK4581","FBT","BK4585","LABU","PSCH","LU0029874061.USD","EOLS","BK4198","BK4137","VNRX","XBI","XLV","LU0128526141.USD","PSIL","HCSG","IBRN","ALKS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649904987","title":"Volitionrx Announces Availability of New Press Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2649904987","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649904987?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:17","pubTimestamp":1783426650,"startTime":"0","endTime":"0","summary":"VolitionRx announces availability of new press releaseVolitionRx released a July 7, 2026 announcement citing a new study on Nu.Q Cancer’s prognostic value in newly diagnosed lung cancer patients.The p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL8d4xkN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649098718","title":"Volitionrx Announces Data Showing the Prognostic Value of Its Nu.q® Cancer Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2649098718","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649098718?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:17","pubTimestamp":1783426620,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA61LLDZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VNRX","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644039259","title":"VolitionRx issues 333,332 shares to Lind to satisfy $416,666 note payment obligation","url":"https://stock-news.laohu8.com/highlight/detail?id=2644039259","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644039259?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:01","pubTimestamp":1781816496,"startTime":"0","endTime":"0","summary":"VolitionRx issued 545,591 common shares to Lind Global Asset Management XII under a $7.5 million senior secured convertible promissory note.Shares covered two $416,666 repayment obligations, issued May 19, 2026  and June 17, 2026 .Transaction was structured as an unregistered issuance, relying on Securities Act exemptions for sales to an existing securityholder.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL5Pr5dp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644035352","title":"VolitionRX Price Target Announced at $4.00/Share by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2644035352","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644035352?lang=en_us&edition=fundamental","pubTime":"2026-06-19 03:29","pubTimestamp":1781810940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VNRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 18, 2026 15:29 ET (19:29 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644746023","title":"VolitionRx Collaborates With Japan's Sysmex for Optimization on Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2644746023","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644746023?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:59","pubTimestamp":1781701167,"startTime":"0","endTime":"0","summary":"VolitionRx  said Wednesday it has entered into a collaboration with Japanese in-vitro diagnostics specialist Sysmex to optimize its Nu.Q NETs H3.1 assay on the Sysmex platform.Financial terms of the collaboration were not provided.The two companies have started the optimization phase of the test in diseases associated with NETosis, which is implicated in diseases such as sepsis, VolitionRx said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4198","VNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745275","title":"VolitionRx partners with Sysmex to optimize Nu.Q NETs H3.1 assay on Sysmex platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745275","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745275?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:15","pubTimestamp":1781698525,"startTime":"0","endTime":"0","summary":"VolitionRx entered a collaboration with Sysmex to optimize its Nu.Q NETs H3.1 assay on the Sysmex platform.Partnership supports VolitionRx’s strategy to out-license the Nu.Q NETs test to global diagnostics groups using their installed analyzer base.Work targets diseases linked to NETosis, including sepsis, positioning the assay for diagnostic use and low-cost patient monitoring.VolitionRx pegged the Nu.Q NETs assay total addressable market at USD 3.8 billion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL53VW1w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745271","title":"VolitionRX Announces Collaboration With Sysmex","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745271","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745271?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:15","pubTimestamp":1781698500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUA8XSS31:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VNRX","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642508447","title":"VolitionRx prices public offering to raise USD 4.6 million upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2642508447","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642508447?lang=en_us&edition=fundamental","pubTime":"2026-06-10 18:02","pubTimestamp":1781085754,"startTime":"0","endTime":"0","summary":"VolitionRx priced a public offering of 2,960,000 common shares with warrants for up to 1,480,000 additional shares.Offering price set at USD 1.55 per share with an accompanying half-warrant; expected gross proceeds about USD 4.6 million.Warrants carry a USD 1.55 exercise price, are exercisable immediately, expire five years from issuance.Full cash exercise could raise about USD 2.3 million in additional gross proceeds; no assurance of exercise.Closing is expected on June 9, 2026, subject to customary conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL8yZ67l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641397171","title":"VolitionRX Announces Pricing of $4.6 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2641397171","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641397171?lang=en_us&edition=fundamental","pubTime":"2026-06-08 06:30","pubTimestamp":1780871401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260607:nTUA7PPM4F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","VNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640902721","title":"VolitionRx files patent covering Nu.Q technology for Ebola triage","url":"https://stock-news.laohu8.com/highlight/detail?id=2640902721","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640902721?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:09","pubTimestamp":1780492147,"startTime":"0","endTime":"0","summary":"VolitionRx (VNRX) announces that it has expanded its intellectual property portfolio by filing a strategic patent application covering the use of i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/volitionrx-files-patent-covering-nu-q-technology-for-ebola-triage-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/volitionrx-files-patent-covering-nu-q-technology-for-ebola-triage-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VNRX","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640901400","title":"VolitionRx files patent application for Nu.Q NETs Ebola triage test","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901400","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901400?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:12","pubTimestamp":1780488748,"startTime":"0","endTime":"0","summary":"VolitionRx filed a patent application covering use of its Nu.Q NETs test to triage suspected Ebola cases and monitor treatment response.Test measures circulating nucleosomes and neutrophil extracellular traps to flag hyper-inflammation risk tied to septic shock and early mortality.Filing targets field use alongside the company’s CE-marked automated Nu.Q NETs lab assay and a finger-prick lateral flow prototype.VolitionRx is seeking strategic partners to run field trials, scale manufacturing, and deploy the lateral flow test in outbreak zones.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL1ScmLQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640901406","title":"VolitionRX - Seeks Partners for Field Trials and Deployment of Lft Prototypes in Outbreak Zones","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901406","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901406?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:12","pubTimestamp":1780488730,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nFWN42B0F3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","VNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640014059","title":"VolitionRX Files New Patent Protecting Its Nu.q® Nets Test for Ebola Triage and Treatment Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2640014059","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640014059?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:12","pubTimestamp":1780488730,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nFWN42B0F3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","VNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638519667","title":"VolitionRx posts corporate deck outlining Nu.Q licensing strategy across cancer, sepsis and veterinary testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638519667","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638519667?lang=en_us&edition=fundamental","pubTime":"2026-05-28 18:59","pubTimestamp":1779965962,"startTime":"0","endTime":"0","summary":"VolitionRx highlighted an asset-light strategy focused on commercial partnerships and out-licensing of its Nu.Q platform across cancer, sepsis, and veterinary testing.Outlined a potential USD 5 million contractual milestone tied to publication of a submitted feline study paper.Reported USD 23 million in licensing to date, with revenue of USD 1 million in Q1 2026.Targeting multiple human-space licensing deals in 2026, following first deals signed in Q3 2025.Flagged reimbursement submission preparations for Nu.Q cancer assays, with an expectation of routine clinical use in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on May 28, 2026, and is solely res","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL31cMvk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638983500","title":"VolitionRx posts $1 million Q1 revenue, up 300% year over year","url":"https://stock-news.laohu8.com/highlight/detail?id=2638983500","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638983500?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:20","pubTimestamp":1779884423,"startTime":"0","endTime":"0","summary":"VolitionRx posted Q1 2026 revenue of USD 1 million, up 300% year over year.Submitted a feline lymphoma manuscript for the Nu.Q Vet cancer test; a USD 5 million milestone payment is expected after publication.Reported active licensing talks with more than a dozen global diagnostics or liquid biopsy groups, including technical evaluations.Capture-Seq validation cohort detected over 95% of Stage I–II cancers with 95% specificity; estimated annualized cancer-detection TAM of USD 23 billion.Nu.Q NETs assay included in France’s DETECSEPS program backed by about USD 7.3 million; sepsis or chronic TAM estimated at USD 3.8 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate thi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL9ZKMT9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638500576","title":"VolitionRx submits peer-reviewed study of Nu.Q Vet feline lymphoma blood test, eyes $5 million milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2638500576","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638500576?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:17","pubTimestamp":1779884273,"startTime":"0","endTime":"0","summary":"VolitionRx flagged a new clinical study milestone with submission of a feline lymphoma manuscript for its Nu.Q Vet blood test.Results have already been presented in the submitted paper; publication is still pending.The study supports the test’s ability to detect feline lymphoma with clinically useful accuracy, positioning it for broader veterinary adoption.Publication is expected to trigger a USD 5 million contractual milestone payment, adding a near-term catalyst for cash inflows.Separately, a planned French DETECSEPS program is set to evaluate the Nu.Q NETs assay for earlier sepsis risk identification later in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this new","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDLkFWQb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637342877","title":"VolitionRx waives Lind note covenant breach, triggers 10% step-up charge","url":"https://stock-news.laohu8.com/highlight/detail?id=2637342877","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637342877?lang=en_us&edition=fundamental","pubTime":"2026-05-23 05:01","pubTimestamp":1779483667,"startTime":"0","endTime":"0","summary":"VolitionRX entered a waiver with Lind Global Asset Management XII on May 21, 2026, tied to its $7.5 million senior secured convertible promissory note issued in May 2025 and its $2.4 million senior secured convertible promissory note issued in January 2026.The waiver removes Lind’s ability to accelerate the notes or foreclose on collateral solely due to a breach of the minimum market-capitalization covenant.The covenant breach triggered an additional amount payable equal to 10% of the outstanding principal amount of each note.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL4BPYFc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.volition.com","stockEarnings":[{"period":"1week","weight":-0.0909},{"period":"1month","weight":-0.187},{"period":"3month","weight":-0.6431},{"period":"6month","weight":-0.8227},{"period":"1year","weight":-0.9315},{"period":"ytd","weight":-0.8044}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company is based in Henderson, Nevada.","yearOnYearQuotes":[{"month":1,"riseRate":0.727273,"avgChangeRate":0.113656},{"month":2,"riseRate":0.272727,"avgChangeRate":-0.085309},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.064923},{"month":4,"riseRate":0.25,"avgChangeRate":-0.053956},{"month":5,"riseRate":0.5,"avgChangeRate":-0.036003},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.029453},{"month":7,"riseRate":0.25,"avgChangeRate":-0.037709},{"month":8,"riseRate":0.545455,"avgChangeRate":0.012627},{"month":9,"riseRate":0.363636,"avgChangeRate":0.038825},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.008979},{"month":11,"riseRate":0.363636,"avgChangeRate":0.018412},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.037586}],"exchange":"AMEX","name":"VolitionRX","nameEN":"VolitionRX"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VolitionRX(VNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest VolitionRX(VNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"VolitionRX,VNRX,VolitionRX股票,VolitionRX股票老虎,VolitionRX股票老虎国际,VolitionRX行情,VolitionRX股票行情,VolitionRX股价,VolitionRX股市,VolitionRX股票价格,VolitionRX股票交易,VolitionRX股票购买,VolitionRX股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VolitionRX(VNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest VolitionRX(VNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}